CD274 and cancer: Compounds which bind target proteins and induce the ubiquitination and subsequent degradation through E3 ligases (Proteolysis Targeting Chimeras, PROTACs) are also being utilised to target PD-L1 in cancer [53, 54], and could serve as a useful, orthogonal treatment avenue to antibody-mediated ICB therapies.